ATLASAllogene Therapeutics (ALLO) earnings date: Nov 5, 2026
Allogene Therapeutics (ALLO) reports earnings for the quarter ended Sep 30, 2026 on Thu, Nov 5, 2026, after the close. Analysts expect EPS of -$0.13.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on ALLO
| Last price | $1.08 (-8.5%) |
|---|---|
| Normal 1-day range (±1σ) | ±3.7% |
| Earnings beat history | Beat the EPS estimate in 2 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Allogene Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Allogene Therapeutics reports on Nov 5, 2026. One email the day before, with ATLAS’s read on Allogene Therapeutics. You can switch it off at any time.
Alert me before ALLO reportsFree to start. Creating an account takes under a minute.
Notify me when Allogene Therapeutics reports
Track ALLO free Add Allogene Therapeutics to a free ATLAS watchlist and see its next report date in one place.
ALLO earnings at a glance
| Next report (confirmed) | Thu, Nov 5, 2026 |
|---|---|
| Time | After the close |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.13 |
| Last report | Aug 12, 2026 · Beat |
| Beat rate (last 5 reports) | 2 of 5 (40%) |
| Average EPS surprise | +5.8% |
| Average move around a report | ±5.6% (last 5) |
| Sector | Healthcare · Biotechnology |
Allogene Therapeutics earnings history: last 5 reports
Allogene Therapeutics last reported on Aug 12, 2026: EPS of -$0.13 against an estimate of -$0.15 (+13.3% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 12, 2026 | -$0.15 | -$0.13 | +13.3% | Beat | -6.6% |
| Jul 18, 2026 | $0.39 | $0.38 | -2.6% | Miss | +3.4% |
| May 13, 2026 | -$0.18 | -$0.18 | 0.0% | In line | -7.0% |
| Mar 12, 2026 | -$0.22 | -$0.17 | +22.7% | Beat | -8.8% |
| Feb 20, 2026 | $1.57 | $1.50 | -4.5% | Miss | -2.4% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for ALLO
See the fair value, the probability range and the earnings history of Allogene Therapeutics on its ATLAS page.
Allogene Therapeutics (ALLO) stock analysisPlans from €3.99 a month.
Allogene Therapeutics earnings: frequently asked questions
When does Allogene Therapeutics (ALLO) report earnings?
Allogene Therapeutics is scheduled to report on Thursday, November 5, 2026, after the close. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for ALLO?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.13 per share (USD). Estimates can change before the report.
How often does ALLO beat earnings estimates?
Of its last 5 reports with a recorded result, Allogene Therapeutics beat the EPS estimate 2 times; the average surprise was +5.8%. Past results do not predict the next one.
How much does ALLO move around earnings?
Over its last 5 reports the stock moved an average of 5.6% (absolute, from the close before the report day to the close after it), and finished higher 1 of 5 times.
Did Allogene Therapeutics beat earnings estimates last quarter?
Allogene Therapeutics last reported on Aug 12, 2026: EPS of -$0.13 against an estimate of -$0.15 (+13.3% surprise), a beat.
How much does ALLO usually move in a day?
On a normal trading day the ATLAS model puts ALLO’s one-day range at about ±3.7%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Thu, Nov 5, 2026
Educational information, not investment advice. Disclaimer